Related content

The effect of follicular antimullerian hormone levels of non-obese, non-hyperandrogenemic polycystic ovary syndrome patients on assisted reproduction outcome

By Yilmaz Nafiye   Uygur Dilek   Dogan Muammer   Ozgu Emre   Salman Burcin   Mollamahmutoglu Leyla  

Gynecological Endocrinology, Vol. 28, Iss. 3, 2012-03 ,pp. : 162-165

Informa Healthcare

Access to resources Recommend Favorite

Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome

By Chen Mei-Jou   Yang Wei-Shiung   Chen Hsin-Fu   Kuo Jahn-Jahn   Ho Hong-Nerng   Yang Yu-Shih   Chen Shee-Uan  

Human Reproduction, Vol. 25, Iss. 3, 2010-03 ,pp. : 779-785

Oxford University Press

Access to resources Recommend Favorite

Plasma β-endorphin levels in obese and non-obese patients with polycystic ovary disease

By Martínez-Guisasola J.   Guerrero M.   Alonso F.   Díaz F.   Cordero J.   Ferrer J.  

Gynecological Endocrinology, Vol. 15, Iss. 1, 2001-02 ,pp. : 14-22

Informa Healthcare

Access to resources Recommend Favorite

Reproductive endocrinology. Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome

By Eldar-Geva T.  

Human Reproduction, Vol. 16, Iss. 12, 2001-12 ,pp. : 2552-2556

Oxford University Press

Access to resources Recommend Favorite

Atherogenic changes in low-density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome

By Kim J.J.   Chae S.J.   Choi Y.M.   Hwang K.R.   Song S.H.   Yoon S.H.   Kim S.M.   Ku S.Y.   Kim S.H.   Kim J.G.   Moon S.Y.  

Human Reproduction, Vol. 28, Iss. 5, 2013-05 ,pp. : 1354-1360

Oxford University Press

Access to resources Recommend Favorite